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Background: The past decade has been a lean period for the dis-
covery of antibiotics with very few approvals of new antibacterial
agents by FDA. However, emergence ofMulti Drug Resistant organ-
isms (MDRO) and Extensively Drug Resistant organisms (XDRO)
pathogens have led to increased attention to this ﬁeld. Center
for Disease Control and Prevention (CDC) has declared infections
caused by MDR ESKAPE pathogens as a critical area of unmet med-
ical need. Further, FDA has also announced various incentives to
support the Infectious Diseases Society of America (IDSA) aspira-
tion to develop 10 new antibiotics by 2020. In this presentation, I
will discuss challenges in the discovery of antibacterial compounds
with a case study of Leucine tRNA synthetase inhibitor (LRSI).
Methods & Materials: Various properties of antibacterial stan-
dard of care agents analyzed with respect to physicochemical,
safety and activity against MDROs/XDROs. Also, merits and demer-
its of novel targets vs. novel approaches were considered. In order
to explore novel targets we have designed, synthesized & pro-
ﬁled novel LRSI. The proﬁle of our compound was compared with
reported LRSI to identify the differentials.
Results: Unlike general drugs, antibacterial compounds need
distinct physicochemical properties in order to work efﬁciently
in different cellular milieu of host & pathogen. Safety (selectiv-
ity & toxicity) is critical as doses required to control the infection
are usually high. New compounds should not only be effective
against MDROs but also possess lower risk of resistance develop-
ment and relapse. We have identiﬁed novel selective Leucine tRNA
synthetase inhibitor (LRSI) for Gram negative MDROs. On analysis
this compound showsdistinct advantages over previously reported
inhibitor.
Conclusion: To circumvent the challenges in the discovery
of antibacterial compounds, the Pharma industry recognizes the
need of novel targets and approaches to tackle the ever evolving
pathogens. Towards this pursuitwe identiﬁed anovel Leucine tRNA
synthetase inhibitor (LRSI) with potent activity against MDROs.
Promising proﬁle of this novel inhibitor merits further develop-
ment for clinical use.
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Abstract: Professor Dame Sally Davies, Chief Medical Ofﬁcer
for England, will set out why Antimicrobial Resistance (AMR) has
become a Global Health Security issue.
She will explain how, through our collective action, AMR has
become a signiﬁcant health issue across the globe and the impact
on health if we do not take collective action to conserve the antimi-
crobials that we have, and encourage the development of new
antimicrobials.
Dame Sally will highlight the need for cross-government
engagement in the ﬁght against AMR – it cannot be seen as a health
issue in isolation, but needs a ‘one-health’ approach.
Finally, Dame Sally will consider the challenges that we face
globally, the international action to date and important next steps.
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Abstract: The number and complexity of tissues being trans-
planted worldwide has increased, which has been made possible
by more centers and well trained teams being involved, and bet-
ter availability of organs. Increasedunderstandingof theworkingof
the immune system, andmore choices in drugs has ensured greater
graft survival with fewer long term complications. Simultaneously,
advances in infection control, and targeted use of prophylactic
agents has resulted in improved overall survival due to reduction in
infections. However, this has resulted in the rise in relative impor-
tance of fungal infections as a cause of morbidity and mortality in
transplant recipients. There have been many advances in this ﬁeld,
and this startswith risk reduction.Betterunderstandingon the time
line of fungal infections have helped us design enhanced infection
control measures like HEPA ﬁlter in stem cell recipients, patient
education on avoidance of high risk situations, a commitment to
de-escalate immune suppression and use of targeted antifungal
prophylaxis. In spite of such interventions, fungal infections con-
tinue to play a role. Early identiﬁcation of patients who are at risk
